Custom Search
Tuesday, June 19, 2007
Newly Released Journal Impact Factors!!!
The journal impactor factors for 2006: top 200 journals.
| Journal Title | Impact Factor |
| CA-CANCER J CLIN | 63.342 |
| NEW ENGL J MED | 51.296 |
| ANNU REV IMMUNOL | 47.237 |
| ANNU REV BIOCHEM | 36.525 |
| REV MOD PHYS | 33.508 |
| NAT REV CANCER | 31.583 |
| PHYSIOL REV | 31.441 |
| NAT REV MOL CELL BIO | 31.354 |
| SCIENCE | 30.028 |
| CELL | 29.194 |
| NAT REV IMMUNOL | 28.697 |
| NAT MED | 28.588 |
| ANNU REV NEUROSCI | 28.533 |
| NAT IMMUNOL | 27.596 |
| NATURE | 26.681 |
| ANNU REV CELL DEV BI | 26.576 |
| CHEM REV | 26.054 |
| LANCET | 25.8 |
| BRIEF BIOINFORM | 24.37 |
| NAT GENET | 24.176 |
| CANCER CELL | 24.077 |
| ENDOCR REV | 23.901 |
| JAMA-J AM MED ASSOC | 23.175 |
| NAT REV NEUROSCI | 23.054 |
| NAT REV GENET | 22.947 |
| ANNU REV PHARMACOL | 22.808 |
| NAT BIOTECHNOL | 22.672 |
| NAT REV DRUG DISCOV | 20.97 |
| ANNU REV PLANT BIOL | 19.837 |
| NAT MATER | 19.194 |
| ANNU REV GENET | 19.098 |
| NAT CELL BIOL | 18.485 |
| IMMUNITY | 18.306 |
| MAT SCI ENG R | 17.731 |
| ACCOUNTS CHEM RES | 17.113 |
| ANNU REV BIOPH BIOM | 16.921 |
| ANNU REV ASTRON ASTR | 16.914 |
| PHARMACOL REV | 16.854 |
| CELL METAB | 16.71 |
| MICROBIOL MOL BIOL R | 15.864 |
| NAT REV MICROBIOL | 15.845 |
| J CLIN INVEST | 15.754 |
| ANNU REV PHYSIOL | 15.356 |
| J NATL CANCER I | 15.271 |
| GENE DEV | 15.05 |
| BEHAV BRAIN SCI | 14.964 |
| NAT METHODS | 14.959 |
| PROG POLYM SCI | 14.818 |
| NAT NEUROSCI | 14.805 |
| ANN INTERN MED | 14.78 |
| ANNU REV MICROBIOL | 14.553 |
| J EXP MED | 14.484 |
| CURR OPIN CELL BIOL | 14.299 |
| TRENDS ECOL EVOL | 14.125 |
| PLOS BIOL | 14.101 |
| MOL CELL | 14.033 |
| ARCH GEN PSYCHIAT | 13.936 |
| NEURON | 13.894 |
| TRENDS BIOCHEM SCI | 13.863 |
| PLOS MED | 13.75 |
| CHEM SOC REV | 13.69 |
| ASTRON ASTROPHYS REV | 13.667 |
| J CLIN ONCOL | 13.598 |
| DEV CELL | 13.523 |
| TRENDS NEUROSCI | 13.494 |
| ANNU REV MED | 13.237 |
| PSYCHOL BULL | 12.725 |
| CLIN MICROBIOL REV | 12.643 |
| AM J HUM GENET | 12.629 |
| ANNU REV FLUID MECH | 12.469 |
| GASTROENTEROLOGY | 12.457 |
| TRENDS CELL BIOL | 12.429 |
| NAT CHEM BIOL | 12.409 |
| PROG LIPID RES | 12.235 |
| NAT PHYS | 12.04 |
| LANCET INFECT DIS | 11.808 |
| MOL PSYCHIATR | 11.804 |
| ANNU REV PSYCHOL | 11.706 |
| CYTOKINE GROWTH F R | 11.549 |
| FRONT NEUROENDOCRIN | 11.526 |
| NAT STRUCT MOL BIOL | 11.502 |
| PROG NEUROBIOL | 11.304 |
| ADV CATAL | 11.25 |
| ANNU REV PHYS CHEM | 11.25 |
| CURR OPIN STRUC BIOL | 11.215 |
| CURR BIOL | 10.988 |
| MASS SPECTROM REV | 10.947 |
| CIRCULATION | 10.94 |
| ANNU REV GENOM HUM G | 10.771 |
| IMMUNOL REV | 10.758 |
| ALDRICHIM ACTA | 10.692 |
| ADV CANCER RES | 10.682 |
| ANNU REV BIOMED ENG | 10.533 |
| ANNU REV NUTR | 10.449 |
| HEPATOLOGY | 10.446 |
| PHYS REP | 10.438 |
| ANNU REV MATER RES | 10.4 |
| TRENDS PHARMACOL SCI | 10.4 |
| GENOME RES | 10.256 |
| ANGEW CHEM INT EDIT | 10.232 |
| PROG MATER SCI | 10.229 |
| TRENDS IMMUNOL | 10.213 |
| CURR OPIN PLANT BIOL | 10.182 |
| J CELL BIOL | 10.152 |
| LANCET ONCOL | 10.119 |
| EMBO J | 10.086 |
| CURR OPIN GENET DEV | 10.006 |
| SEMIN IMMUNOL | 10 |
| NANO LETT | 9.96 |
| TRENDS GENET | 9.95 |
| PLANT CELL | 9.868 |
| CIRC RES | 9.854 |
| ANNU REV ECOL EVOL S | 9.784 |
| J AM COLL CARDIOL | 9.701 |
| P NATL ACAD SCI USA | 9.643 |
| MOL CELL PROTEOMICS | 9.62 |
| REP PROG PHYS | 9.549 |
| SOLID STATE PHYS | 9.5 |
| LANCET NEUROL | 9.479 |
| CURR OPIN IMMUNOL | 9.422 |
| CRIT REV BIOCHEM MOL | 9.393 |
| ADV PHYS | 9.389 |
| TRENDS COGN SCI | 9.374 |
| SURF SCI REP | 9.304 |
| CURR OPIN NEUROBIOL | 9.286 |
| RECENT PROG HORM RES | 9.263 |
| BRIT MED J | 9.245 |
| CATAL REV | 9.222 |
| BBA-REV CANCER | 9.156 |
| AM J RESP CRIT CARE | 9.091 |
| PROG RETIN EYE RES | 9.039 |
| GUT | 9.002 |
| ANNU REV PHYTOPATHOL | 9 |
| NAT PROD REP | 8.889 |
| J ALLERGY CLIN IMMUN | 8.829 |
| PSYCHOL REV | 8.825 |
| COORDIN CHEM REV | 8.815 |
| ANNU REV ENTOMOL | 8.714 |
| FEMS MICROBIOL REV | 8.691 |
| SEMIN CELL DEV BIOL | 8.672 |
| PHARMACOL THERAPEUT | 8.657 |
| ASTROPHYS J SUPPL S | 8.627 |
| REV GEOPHYS | 8.375 |
| REJUV RES | 8.353 |
| TRENDS MICROBIOL | 8.335 |
| CURR OPIN CHEM BIOL | 8.32 |
| EPIDEMIOL REV | 8.3 |
| NEUROSCI BIOBEHAV R | 8.293 |
| AM J PSYCHIAT | 8.25 |
| EMBO REP | 8.175 |
| HUM MOL GENET | 8.099 |
| CLIN PHARMACOL THER | 8.066 |
| ANN NEUROL | 8.051 |
| TRENDS PLANT SCI | 8 |
| ADV DRUG DELIVER REV | 7.977 |
| DIABETES | 7.955 |
| MOL SYST BIOL | 7.941 |
| STEM CELLS | 7.924 |
| ARCH INTERN MED | 7.92 |
| DIABETES CARE | 7.912 |
| ADV MATER | 7.896 |
| TRENDS BIOTECHNOL | 7.843 |
| ADV MICROB PHYSIOL | 7.818 |
| DEVELOPMENT | 7.764 |
| ARTH RHEUM/AR C RES | 7.751 |
| SYSTEMATIC BIOL | 7.748 |
| J AM CHEM SOC | 7.696 |
| ANNU REV EARTH PL SC | 7.683 |
| ANN SURG | 7.678 |
| PLOS GENET | 7.671 |
| CANCER RES | 7.656 |
| BRAIN | 7.617 |
| ECOL LETT | 7.609 |
| MUTAT RES-REV MUTAT | 7.579 |
| CELL DEATH DIFFER | 7.463 |
| J NEUROSCI | 7.453 |
| GLYCOCONJUGATE J | 7.446 |
| CURR OPIN MICROBIOL | 7.445 |
| SEMIN CANCER BIOL | 7.378 |
| J AM SOC NEPHROL | 7.371 |
| J PHOTOCH PHOTOBIO C | 7.32 |
| EUR HEART J | 7.286 |
| PHARMACOGENETICS | 7.221 |
| MED RES REV | 7.218 |
| GENOME BIOL | 7.172 |
| BIOL PSYCHIAT | 7.154 |
| DRUG DISCOV TODAY | 7.152 |
| ECOL MONOGR | 7.102 |
| PHYS REV LETT | 7.072 |
| TRENDS ENDOCRIN MET | 7.066 |
| PROG HISTOCHEM CYTO | 7 |
| CURR OPIN BIOTECH | 6.949 |
| CURR OPIN PHARMACOL | 6.916 |
| BBA-MOL CELL RES | 6.9 |
| ARTERIOSCL THROM VAS | 6.883 |
| CAN MED ASSOC J | 6.862 |
| ANNU REV PUBL HEALTH | 6.854 |
| ADV ORGANOMET CHEM | 6.85 |
| AM J TRANSPLANT | 6.843 |
| MILBANK Q | 6.794 |
What about Journal Impact Factors?
Journal Impact Factor is from Journal Citation Report (JCR), a product of Thomson ISI (Institute for Scientific Information). JCR provides quantitative tools for evaluating journals. The impact factor is one of these; it is a measure of the frequency with which the "average article" in a journal has been cited in a given period of time.
The impact factor for a journal is calculated based on a three-year period, and can be considered to be the average number of times published papers are cited up to two years after publication. For example, the impact factor 2007 for a journal would be calculated as follows:
A = the number of times articles published in 2005-6 were cited in indexed journals during 2007
B = the number of articles, reviews, proceedings or notes published in 2005-6
impact factor 2007 = A/B
(note that the impact factor 2006 will be actually published in 2007, because it could not be calculated until all of the 2007 publications had been received. Impact factor 2007 will be published in 2008)
The impact factor for a journal is calculated based on a three-year period, and can be considered to be the average number of times published papers are cited up to two years after publication. For example, the impact factor 2007 for a journal would be calculated as follows:
A = the number of times articles published in 2005-6 were cited in indexed journals during 2007
B = the number of articles, reviews, proceedings or notes published in 2005-6
impact factor 2007 = A/B
(note that the impact factor 2006 will be actually published in 2007, because it could not be calculated until all of the 2007 publications had been received. Impact factor 2007 will be published in 2008)
Wednesday, June 6, 2007
NIBR Presidential Postdoctoral Fellowship Program
Novatis is a leading pharmaceutical company worldwide, total sales of 2006 over 37 billion US dollars and its R&D spending about 5.4 billion dollars during last year.
The Novartis Institutes for BioMedical Research (NIBR) is Novartis’ global research organization. Its headquarter is located in Cambridge, Massachusetts, USA. The scientific environment at the Novartis Institutes for BioMedical Research (NIBR) is open, collegial, collaborative and entrepreneurial.
The Presidential Postdoctoral Fellow Program of the Novartis Institutes for BioMedical Research (NIBR) is one of the best industry postdoctoral programs, and very competitive. The training will be industrial and also academic oriented. So after postdoctoral tenure, the trainees can either stay in industry or go back to academia. Generally it is impossible for industry people to switch back to academy after several years. However, it appears that these top industry postdoctoral programs will provide trainees more career freedom and options after training.
Graduate students within 1 year of completing their doctoral work and postdoctoral fellows nearing completion of their first postdoctoral training period (within 3 years of obtaining their PhD) are eligible to apply.
The selection process is very selective! But your efforts will be paid off !
Needless to say its generous salary and excellent compensatory package!
The Novartis Institutes for BioMedical Research (NIBR) is Novartis’ global research organization. Its headquarter is located in Cambridge, Massachusetts, USA. The scientific environment at the Novartis Institutes for BioMedical Research (NIBR) is open, collegial, collaborative and entrepreneurial.
The Presidential Postdoctoral Fellow Program of the Novartis Institutes for BioMedical Research (NIBR) is one of the best industry postdoctoral programs, and very competitive. The training will be industrial and also academic oriented. So after postdoctoral tenure, the trainees can either stay in industry or go back to academia. Generally it is impossible for industry people to switch back to academy after several years. However, it appears that these top industry postdoctoral programs will provide trainees more career freedom and options after training.
Graduate students within 1 year of completing their doctoral work and postdoctoral fellows nearing completion of their first postdoctoral training period (within 3 years of obtaining their PhD) are eligible to apply.
The selection process is very selective! But your efforts will be paid off !
Needless to say its generous salary and excellent compensatory package!
Sunday, June 3, 2007
Top Ten Advices to Young Scientists
Michael M. Merzenich, a well-known neuroscientist from UCSF, a member of National Academy of Sciences, when interviewed by the International Brain Research Organization, gave his valuable opinions about a number of interesting issues. most importantly, I really like his advice to young generation.
Michael M. Merzenich contributions to this world are numerous. Besides being a great researcher, he is the co-founder of two companies, Scientific Learning and Posit Science. Both are working on a broad range of behavioral therapies, which grew out of his pioneering scientific discoveries.
His top ten:
1) Read: Educate yourself about the history of your science. Work hard to ground yourself in the historical and current context of your scientific question(s).
2) Your sense of reason is actually your greatest scientific tool, far more useful than any other instrument in your laboratory. Use it.
3) Adopt an issues-directed, rather than a method-directed approach to science. If the fastest way to make progress is to apply a new method, don’t be cowed by your methodological ignorance. Learn it, or find a collaborator to help.
4) Develop an organized plan for your own personal training and development. There is a lot for you to know and understand, and multiple methodologies that you must master, if you are going to operate in science at the highest level. It is crucial that you systematically prepare yourself for your future great good works.
5) Work on the creation of a logical superstructure that extends widely across your scientific arena. Don’t forget to water and fertilize your logical garden. Measure progress by how far, how fast, and how securely you can advance that logical frame.
6) Take the carefully collected data of other scientists seriously. Work to sharpen your ability to distinguish between their observations, and their arguments. Respect the former; the latter are just arguments. Remember that carefully collected data (yours or others’) that do not fit your logical frame can be more valuable than data that do.
7) Most modern science is team science. Work on the development of your leadership and mentorship abilities, because they will critically enable – or limit – your ‘personal’ achievements.
8) Actively seek extensions of your science out into the ‘real world’. If you discover one, see that you (or someone else with the requisite ability and energy) exploit(s) it.
9) Science is not just a career. It is an honored profession. Your value as a scientist is not measured by job security or external acclaim. What counts: Studies that make a difference. Studies that advance our understanding. Studies that last.
10) Be a good citizen-scientist. Accept your responsibility for playing an active role in educating the wider public about the importance and societal value of real science.
His interview full transcript is available here.Michael M. Merzenich contributions to this world are numerous. Besides being a great researcher, he is the co-founder of two companies, Scientific Learning and Posit Science. Both are working on a broad range of behavioral therapies, which grew out of his pioneering scientific discoveries.
Friday, June 1, 2007
Industry Postdoc Programs-CIIT
I am going to introduce you some well-established industry postdoc programs. Generally, if you get postdoc training in industry, you will have a much better chance to be hired by industry.
Genentech postdoc program is my favorite one. Don't be sad, if Genentech dumped you. There are quite a few top companies or organizations offering postdoc training.
CIIT, a private, not-for-profit research organization, mainly focus on toxicology, chemical biology, environmental sciences, human health risk assessments and pharmacology.
CIIT has strong ties with industry. Most of its trainees are employed in industry after postdoc tenure. Here is the statement on the website:
"Since beginning operations in 1976, CIIT has trained over 200 postdoctoral fellows who are now enjoying rewarding careers in academia, government, and industry. Approximately 35% of former CIIT fellows are employed in the pharmaceutical industry, 25% in the chemical industry, 21% in other industries, 12% at academic institutions, and 7% at government research facilities."
Although the salary and benefits for postdoc fellows are not listed on the website. But I heard it is pretty competitive nationally. Plus it is located in one of the best places in US, Research Triangle Park, North Carolina, which is also the home of the National Institute of Environmental Health Sciences.
Click here for its excellent postdoc training program!
Genentech postdoc program is my favorite one. Don't be sad, if Genentech dumped you. There are quite a few top companies or organizations offering postdoc training.
CIIT, a private, not-for-profit research organization, mainly focus on toxicology, chemical biology, environmental sciences, human health risk assessments and pharmacology.
CIIT has strong ties with industry. Most of its trainees are employed in industry after postdoc tenure. Here is the statement on the website:
"Since beginning operations in 1976, CIIT has trained over 200 postdoctoral fellows who are now enjoying rewarding careers in academia, government, and industry. Approximately 35% of former CIIT fellows are employed in the pharmaceutical industry, 25% in the chemical industry, 21% in other industries, 12% at academic institutions, and 7% at government research facilities."
Although the salary and benefits for postdoc fellows are not listed on the website. But I heard it is pretty competitive nationally. Plus it is located in one of the best places in US, Research Triangle Park, North Carolina, which is also the home of the National Institute of Environmental Health Sciences.
Click here for its excellent postdoc training program!
Subscribe to Posts [Atom]